Literature DB >> 17210699

hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site.

Rebekah L Zinn1, Kevin Pruitt, Sayaka Eguchi, Stephen B Baylin, James G Herman.   

Abstract

hTERT, which encodes the catalytic subunit of telomerase and is expressed in most immortalized and cancer cells, has been reported to have increased DNA methylation in its promoter region in many cancers. This pattern is inconsistent with observations that DNA methylation of promoter CpG islands is typically associated with gene silencing. Here, we provide a comprehensive analysis of promoter DNA methylation, chromatin patterns, and expression of hTERT in cancer and immortalized cells. Methylation-specific PCR and bisulfite sequencing of the hTERT promoter in breast, lung, and colon cancer cells show that all cancer cell lines retain alleles with little or no methylation around the transcription start site despite being densely methylated in a region 600 bp upstream of the transcription start site. By real-time reverse transcription-PCR, all cancer cell lines express hTERT. Chromatin immunoprecipitation (ChIP) analysis reveals that both active (acetyl-H3K9 and dimethyl-H3K4) and inactive (trimethyl-H3K9 and trimethyl-H3K27) chromatin marks are present across the hTERT promoter. However, using a novel approach combining methylation analysis of ChIP DNA, we show that active chromatin marks are associated with unmethylated DNA, whereas inactive marks of chromatin are associated with methylated DNA in the region around the transcription start site. These results show that DNA methylation patterns of the hTERT promoter (-150 to +150 around the transcription start) are consistent with the usual dynamics of gene expression in that the absence of methylation in this region and the association with active chromatin marks allow for the continued expression of hTERT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210699     DOI: 10.1158/0008-5472.CAN-06-3396

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  99 in total

1.  Long-term stability of demethylation after transient exposure to 5-aza-2'-deoxycytidine correlates with sustained RNA polymerase II occupancy.

Authors:  Jacob D Kagey; Priya Kapoor-Vazirani; Michael T McCabe; Doris R Powell; Paula M Vertino
Journal:  Mol Cancer Res       Date:  2010-06-29       Impact factor: 5.852

Review 2.  Telomere biology: Rationale for diagnostics and therapeutics in cancer.

Authors:  Philippe Rousseau; Chantal Autexier
Journal:  RNA Biol       Date:  2015-08-20       Impact factor: 4.652

3.  Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.

Authors:  Xin Zhao; Xin Tian; Sachiko Kajigaya; Caroline R Cantilena; Stephen Strickland; Bipin N Savani; Sanjay Mohan; Xingmin Feng; Keyvan Keyvanfar; Neil Dunavin; Danielle M Townsley; Bogdan Dumitriu; Minoo Battiwalla; Katayoun Rezvani; Neal S Young; A John Barrett; Sawa Ito
Journal:  Br J Haematol       Date:  2016-07-19       Impact factor: 6.998

Review 4.  An overview of epigenetic assays.

Authors:  J Tyson DeAngelis; Woodrow J Farrington; Trygve O Tollefsbol
Journal:  Mol Biotechnol       Date:  2007-10-18       Impact factor: 2.695

5.  Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG.

Authors:  Joel B Berletch; Canhui Liu; William K Love; Lucy G Andrews; Santosh K Katiyar; Trygve O Tollefsbol
Journal:  J Cell Biochem       Date:  2008-02-01       Impact factor: 4.429

6.  DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.

Authors:  Donghyun D Lee; Ricardo Leão; Martin Komosa; Marco Gallo; Cindy H Zhang; Tatiana Lipman; Marc Remke; Abolfazl Heidari; Nuno Miguel Nunes; Joana D Apolónio; Aryeh J Price; Ramon Andrade De Mello; João S Dias; David Huntsman; Thomas Hermanns; Peter J Wild; Robert Vanner; Gelareh Zadeh; Jason Karamchandani; Sunit Das; Michael D Taylor; Cynthia E Hawkins; Jonathan D Wasserman; Arnaldo Figueiredo; Robert J Hamilton; Mark D Minden; Khalida Wani; Bill Diplas; Hai Yan; Kenneth Aldape; Mohammad R Akbari; Arnavaz Danesh; Trevor J Pugh; Peter B Dirks; Pedro Castelo-Branco; Uri Tabori
Journal:  J Clin Invest       Date:  2018-12-03       Impact factor: 14.808

7.  hTERT methylation is necessary but not sufficient for telomerase activity in colorectal cells.

Authors:  Cristina Valls-Bautista; Stéphanie Bougel; Carme Piñol-Felis; Joan Viñas-Salas; Jean Benhattar
Journal:  Oncol Lett       Date:  2011-08-18       Impact factor: 2.967

8.  Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines.

Authors:  Syed M Meeran; Shweta N Patel; Trygve O Tollefsbol
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

9.  A role for methyl-CpG binding domain protein 2 in the modulation of the estrogen response of pS2/TFF1 gene.

Authors:  Amandine Chatagnon; Esteban Ballestar; Manel Esteller; Robert Dante
Journal:  PLoS One       Date:  2010-03-12       Impact factor: 3.240

10.  hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis.

Authors:  Jillian de Wilde; Jan M Kooter; Renée M Overmeer; Debbie Claassen-Kramer; Chris J L M Meijer; Peter J F Snijders; Renske D M Steenbergen
Journal:  BMC Cancer       Date:  2010-06-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.